Ignite Creation Date:
2024-05-06 @ 12:16 AM
Last Modification Date:
2024-10-26 @ 10:47 AM
Study NCT ID:
NCT01534260
Status:
COMPLETED
Last Update Posted:
2018-08-17
First Post:
2012-02-13
Brief Title:
Phase III Study of Combination of Sorafenib Vorinostat and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk Monosomy 57 Cytogenetics or FLT3-ITD Positive Genotype
Sponsor:
Hamid Sayar
Organization:
Indiana University
Study Overview
Official Title:
Phase III Study of Combination of Sorafenib Vorinostat and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk Monosomy 57 Cytogenetics or FLT3-ITD Positive Genotype
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research is being done because treatment options are very limited and usually unsuccessful for Acute Myeloid Leukemia AML in older individuals or younger people with disease that has relapsed andor proven resistant to standard therapy Subjects are invited to participate in this study that will examine the use of three drugs called Sorafenib Nexavar Vorinostat Zolinza and Bortezomib Velcade for treating acute myeloid leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1110007281 | OTHER | Indiana University IRB | None |